Pharming Q3 EPS $(0.002) Misses $0.01 Estimate, Sales $74.80M Miss $76.93M Estimate
Portfolio Pulse from Benzinga Newsdesk
Pharming (NASDAQ:PHAR) reported a Q3 EPS of $(0.002), missing the $0.01 estimate, and sales of $74.80M, missing the $76.93M estimate. Despite the misses, sales increased by 12.14% compared to the same period last year.
October 24, 2024 | 5:40 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pharming's Q3 earnings report showed a significant miss on EPS and a slight miss on sales estimates. The EPS was $(0.002) against an expected $0.01, and sales were $74.80M versus $76.93M expected. However, sales increased by 12.14% year-over-year.
The significant miss on EPS and slight miss on sales estimates are likely to negatively impact Pharming's stock price in the short term. The market often reacts unfavorably to earnings misses, especially when the EPS miss is substantial. However, the year-over-year sales growth may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100